Covid19 Clinical Trial
Official title:
Incidence of Postoperative Delirium After Cardiac Surgery in Adults - a Prospective Observational Cohort Study
Postoperative delirium is an acute syndrome of mental deterioration characterized by acute onset and fluctuating course during the day. Very frequent delirium is a presage of other serious comorbidities i.e.: sepsis, acute kidney injury, circulatory and/or respiratory failure. A detailed knowledge of symptoms and early diagnose of delirium increase the chances of early therapy. To what extent the occurrence of postoperative delirium influences hospital therapy in the Cardiac Surgical Postoperative ICU in University Clinical Centre in GdaĆsk is unknown so far.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | August 31, 2022 |
Est. primary completion date | January 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (>18 y.a.), undergoing cardiac surgery, who will sign an informed consent to participate in the study. Exclusion Criteria: - Deny to sign or absence of an informed consent. |
Country | Name | City | State |
---|---|---|---|
Poland | Department of Cadiac Anesthesiology, Medical University of Gdansk | Gdansk | Pomorskie |
Lead Sponsor | Collaborator |
---|---|
Medical University of Gdansk |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Delirium incidence and risk | Incidence and risk of postoperative delirium | Through hospitalisation in Postop-ICU - an average of 2 days | |
Primary | Risk factors of delirium. | collected will be known risk factors of delirium: schedule type, age, arterial hypertension, atrial fibrillation, BMI, ACE/ARBs therapy, hearing loss, dementia, peripheral artery disease, myocardial infarction, depression, diabetes, COVID19 and/or vaccination for it; and outcome data: hospital-LOS, prolonged sedation, antipsychotic therapy, surgical reintervention, direct coercion, length of mechanical ventilation, number of tracheal intubations, length of consciousness disorders, blood product transfusions, cardiopulmonary resuscitation, renal replacement therapy, mechanical circulatory support, duration of catecholamine support, ICU readmissions, new antibiotic therapies, 30-day mortality. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Primary | Association between delirium and length of stay in ICU (LOS-ICU). | Association between delirium and length of stay in ICU (LOS-ICU). | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | DOSS | Associations between delirium and mean DOSS | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Hospital-LOS | Association between delirium and hospital-LOS | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Prolonged sedation, antipsychotic therapy and surgical re-intervention. | Association between delirium and prolonged sedation, antipsychotic therapy, surgical reintervention. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Hours on ventilator. | Association between delirium and HOV. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Intubations | Association between delirium and number of tracheal intubations. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Consciousness disorders | Association between delirium and length of consciousness disorders. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Transfusions | Association between delirium and blood product transfusions. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | CPR, RRT, MCS | Association between delirium and CPR, RRT, and MCS. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | Catecholamines | Association between delirium and duration of catecholamine support. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | ICU readmissions | Association between delirium and ICU readmissions. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | New antibiotic | Association between delirium and new antibiotic therapy. | Through hospitalisation in Postop-ICU - an average of 2 days | |
Secondary | 30-day mortality | Association between delirium and 30-day mortality | 30 days after operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |